Dickinson Andrew D 4

What Happened
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), sold 3,000 shares in an open-market/private sale on April 15, 2026 at $140.96 per share, for total proceeds of $422,880. This was a sale (not a purchase), which for reporting purposes is typically viewed as routine insider selling unless otherwise noted.

Key Details

• Transaction date: April 15, 2026; filed on April 16, 2026 (timely filing).
• Price and amount: 3,000 shares at $140.96 per share; total value $422,880.
• Transaction type: Sale (code S) via open market or private sale as reported.
• Shares owned after transaction: Not specified in the Form 4 provided.
• Footnote: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted August 29, 2024 (pre-arranged plan).
• Filing timeliness: Reported the next day (not marked late).

Context
A 10b5-1 plan indicates the sale was conducted under a pre-established trading arrangement, which can mean the trade was scheduled in advance and not necessarily reflective of the insider’s current view of the company. In general, purchases may signal stronger insider conviction than routine sales; this filing documents a planned disposition rather than an option exercise or gift.